CompletedNot applicableNCT00053157
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
Studying Acute mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Roswell Park Cancer Institute
- Principal Investigator
- Philip L. McCarthy, MDRoswell Park Cancer Institute
- Intervention
- sargramostim(biological)
- Enrollment
- 10 enrolled
- Eligibility
- 5-60 years · All sexes
- Timeline
- 2002
Study locations (1)
- Roswell Park Cancer Institute, Buffalo, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00053157 on ClinicalTrials.govOther trials for Acute mast cell leukemia
Additional recruiting or active studies for the same condition.